Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, longitudinal real life study to demonstrate the glycemic control, weight and body composition changes with the use of Exenatide LAR/Dapagliflozin combination in Obese Type 2 Diabetes Patients in Mexico

Trial Profile

An open, longitudinal real life study to demonstrate the glycemic control, weight and body composition changes with the use of Exenatide LAR/Dapagliflozin combination in Obese Type 2 Diabetes Patients in Mexico

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs Dapagliflozin (Primary) ; Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top